News | January 06, 2022
Margins under pressure; domestic market growth to slow down: Nirmal Bang
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
Subscribe To Our Newsletter & Stay Updated
